Results 31 to 40 of about 1,653 (153)

Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review

Frontiers in Oncology, 2022
Globally, prostate cancer is one of the most common malignancies affecting men. With the advent of advanced molecular imaging, an increasing number of men are found to have oligometastatic disease (OD) either at primary diagnosis or at the time of ...
Alexander Yaney, Andrew Stevens, Paul Monk, Douglas Martin, Dayssy A. Diaz, Shang-Jui Wang   +5 more
doaj   +1 more source

The role of stereotactic body radiotherapy in the management of oligometastatic soft tissue and bone sarcomas

Nowotwory, 2023
Sarcomas are a highly heterogeneous group of rare malignancies. Historically, metastatic disease was considered incurable and was an indication for a palliative approach.
Konrad Zasadziński, Mateusz J. Spałek
doaj   +1 more source

Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer

, 2022
Introduction: Some patients with cancer may present with progressive or persistent disease at a limited number of sites following a period of treatment response.
박은정, 장지석, 금웅섭, 변화경, 안중배, 신상준, 김한상, 김미선, 양고운, 이정심, 범승훈   +10 more
core   +1 more source

Stereotactic body radiation therapy (SBRT) of adrenal gland metastases in oligometastatic and oligoprogressive disease [PDF]

, 2021
BACKGROUND: Stereotactic body radiation therapy (SBRT) as a form of noninvasive treatment that is becoming increasingly used to manage cancers with adrenal gland metastases. There is a paucity of data on safety and efficacy of this modality.
Silverman, Craig L.; Department of Radiation Oncology, James Graham Brown Cancer Center, University of Louisville School of Medicine, Louisville, United States of America, Reshko, Leonid B.; Department of Radiation Oncology, James Graham Brown Cancer Center, University of Louisville School of Medicine, Louisville, United States of America, Gaskins, Jeremy T.; Department of Bioinformatics & Biostatistics, University of Louisville School of Public Health and Information Sciences, Louisville, United States of America, Dunlap, Neal E.; Department of Radiation Oncology, James Graham Brown Cancer Center, University of Louisville School of Medicine, Louisville, United States of America   +3 more
core   +2 more sources

Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study [PDF]

, 2019
PURPOSE: Herein, we report the clinical outcomes of a multicenter study evaluating the role of SBRT in a cohort of patients affected by oligoprogressive castration-resistant prostate cancer (CRPC).
Bortolus, Roberto, Bruni, Alessio, Franzese, Ciro, Jereczek-Fossa, Barbara Alicja, Triggiani, Luca, Mazzeo, Ercole, Matrone, Fabio, Buglione, Michela, Francolini, Giulio, Bonù, Marco Lorenzo, Trippa, Fabio, Paiar, Fabiola, Borghetti, Paolo, Detti, Beatrice, Fanetti, Giuseppe, Pasqualetti, Francesco, Alongi, Filippo, Ingrosso, Gianluca, Mazzola, Rosario, Lancia, Andrea, Ost, Piet, Maranzano, Ernesto, Scorsetti, Marta, Magrini, Stefano Maria, Magli, Alessandro   +24 more
core   +2 more sources

Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE): a non-randomized phase 2 trial

BMC Cancer, 2020
Background Patients diagnosed with metastatic castration-refractory prostate cancer (mCRPC) rely on a limited number of therapeutic agents resulting in a median survival of 2–3 years. A subgroup of those patients with mCRPC presents with oligoprogressive
Charlien Berghen, Steven Joniau, Kato Rans, Gaëtan Devos, Kenneth Poels, Koen Slabbaert, Herlinde Dumez, Maarten Albersen, Karolien Goffin, Karin Haustermans, Gert De Meerleer   +10 more
doaj   +1 more source

Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration‐resistant prostate cancer patients during abiraterone/enzalutamide treatment

, 2021
Background Metastasis-directed therapy (MDT) utilizing stereotactic body radiotherapy (SBRT) for oligoprogressive lesions could provide a delay in next-line systemic treatment (NEST) change while undergoing androgen receptor-targeted agents (ARTA ...
Tilki, BURAK, Akyol, Fadil, Aksoy, Sercan, Fatih Kose, Burak Tilki, Oymak, Ezgi, Muallaoglu, Sadik, Kose, Fatih, Fadil Akyol, Onal, Cem, Hurmuz, Pervin, Cem Onal, Ozyigit, Gokhan, Ezgi Oymak, Pervin Hurmuz, Gokhan Ozyigit, Sercan Aksoy, Sadik Muallaoglu, Ozan C. Guler, Guler, Ozan C   +19 more
core   +1 more source

Hypofractionated Radiation Therapy for Unresectable or Metastatic Sarcoma Lesions

Advances in Radiation Oncology, 2022
Purpose: Given the relative radioresistance of sarcomas and their often large size, conventional palliative radiation therapy (RT) often offers limited tumor control and symptom relief.
David Boyce-Fappiano, MD, MHM, Ethan P. Damron, BS, Ahsan Farooqi, MD, PhD, Devarati Mitra, MD, PhD, Anthony P. Conley, MD, Neeta Somaiah, MD, Dejka M. Araujo, MD, J. Andrew Livingston, MD, Ravin Ratan, MD, MEd, Emily Z. Keung, MD, Christina L. Roland, MD, MS, B. Ashleigh Guadagnolo, MD, MPH, Andrew J. Bishop, MD   +12 more
doaj   +1 more source

Re-irradiation for oligoprogression under Nivolumab in recurrent head and neck squamous cell carcinoma: A case report

Clinical and Translational Radiation Oncology, 2020
Immune checkpoint inhibitors (ICIs) represent a recently introduced class of agents active in head and neck squamous cell carcinoma (HNSCC). For a subgroup of patients with recurrent or metastatic disease, long-term benefit can be achieved: maintaining a
Pierluigi Bonomo, Sara Lucidi, Isacco Desideri, Vieri Scotti, Marta Casati, Annarita Palomba, Cinzia Ciabatti, Pietro Garlatti, Daniela Massi, Oreste Gallo, Lorenzo Livi   +10 more
doaj   +1 more source

Treatment of Metastatic Her2Neu+ Breast Cancer with Oligoprogressive Disease [PDF]

Background Information: In treating metastatic Her2Neu+ breast cancer, trastuzumab-based chemotherapy regimens typically result in fairly durable tumor control.
Ayub, Jinan, Newton, Erin, Kenyon, Taylor, Ramchandani, Muskaan, Pelton, Sarah   +4 more
core   +3 more sources